TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$4,50
Dagwisseling
$4,47 - $4,62
Jaarwisseling
$2,71 - $5,10
Markkapitalisasie
883,56 m USD
Gemiddelde volume
2,67 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,05 m | -33,23% |
Bedryfskoste | 3,69 m | -21,71% |
Netto inkomste | -3,76 m | 70,03% |
Netto winsgrens | -357,37 | 55,11% |
Wins per aandeel | — | — |
EBITDA | -7,63 m | 34,28% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 91,47 m | -25,40% |
Totale bates | 94,62 m | -28,16% |
Totale aanspreeklikheid | 18,04 m | -47,46% |
Totale ekwiteit | 76,58 m | — |
Uitstaande aandele | 195,48 m | — |
Prys om te bespreek | 11,25 | — |
Opbrengs op bates | -19,87% | — |
Opbrengs op kapitaal | -23,48% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -3,76 m | 70,03% |
Kontant van bedrywe | -4,68 m | 54,63% |
Kontant van beleggings | -1,36 m | -110,15% |
Kontant van finansiering | 1,64 m | 15,41% |
Netto kontantverandering | -4,40 m | -198,13% |
Beskikbare kontantvloei | -1,95 m | 77,37% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
19
